Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018155 | 0.96 | MAPT (0.52) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL2021192 | 0.96 | MAPT (0.52) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL2018158 | 0.96 | MAPT (0.52) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL2020239 | 0.87 | KDM4E (0.62) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL2018427 | 0.85 | KDM4E (0.60) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL2017069 | 0.85 | KDM4E (0.60) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL16105705 | 0.84 | TNF (0.49) | ALDH1A1 | |
| SCHEMBL2021218 | 0.84 | KDM4E (0.59) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL2019249 | 0.83 | MEN1 (0.60) | MAPTLMNAKDM4ENPSR1HTT | |
| SCHEMBL2016729 | 0.82 | KDM4E (0.57) | MAPTLMNAKDM4ENPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2019-11-07 | — | — | US | disclosed |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | TRANSTECH PHARMA, INC. | 2018-12-20 | — | — | US | disclosed |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180071297-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | VTV THERAPEUTICS LLC | 2018-03-15 | — | — | US | disclosed |
| US-9833457-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170252343-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | VTV THERAPEUTICS LLC | 2017-09-07 | — | — | US | disclosed |
| US-9687489-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160296526-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | VTV THERAPEUTICS LLC | 2016-10-13 | — | — | US | disclosed |
| US-20140371250-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | VTV THERAPEUTICS LLC | 2014-12-18 | — | — | US | disclosed |
| US-8853226-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2244574-B1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF- SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8329715-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120172381-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110160234-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-7964608-B2 | Tricyclic compounds as modulators of TNF-α synthesis | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2244574-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF- SYNTHESIS AND AS PDE4 INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100190808-A1 | Tricyclic Compounds As Modulators of TNF-alpha Synthesis | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2009094528-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371250-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | PDE4A, PDE4B, TNF | MAPT 3323/4885LMNA 3646/4885KDM4E 1235/4885 |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, TNF | MAPT 2854/4885LMNA 3622/4885KDM4E 1478/4885 |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | MAPT 2672/4885LMNA 4285/4885KDM4E 1135/4885 |
| US-20100190808-A1 | Tricyclic Compounds As Modulators of TNF-alpha Synthesis | TNF, PDE4A, PDE4B | MAPT 3265/4885LMNA 3829/4885KDM4E 1810/4885 |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, TNF | MAPT 2854/4885LMNA 3622/4885KDM4E 1478/4885 |
| US-20110160234-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | PDE4A, PDE4B, TNF | MAPT 3323/4885LMNA 3646/4885KDM4E 1235/4885 |
| US-20120172381-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | PDE4A, PDE4B, TNF | MAPT 3323/4885LMNA 3646/4885KDM4E 1235/4885 |
| US-20180071297-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | MAPT 2672/4885LMNA 4285/4885KDM4E 1135/4885 |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | PDE4A, TNF, PDE4B | MAPT 2406/4885LMNA 4332/4885KDM4E 1009/4885 |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | MAPT 2672/4885LMNA 4285/4885KDM4E 1135/4885 |
| US-20170252343-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | TNF, PDE4A, PDE4B | MAPT 1928/4885LMNA 3250/4885KDM4E 1292/4885 |
| US-20160296526-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, TNF, PDE4B | MAPT 1995/4885LMNA 3556/4885KDM4E 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.